The researchers found that the treatments did not differ
significantly on any abstinence outcome measure at 26 or 52 weeks, including point - prevalence abstinence at 26 weeks (nicotine patch, 23 percent; varenicline, 24 percent; C - NRT, 27 percent) or at 52 weeks (nicotine patch, 21 percent; varenicline, 19 percent; C - NRT, 20 percent).